PMID- 26980581
OWN - NLM
STAT- MEDLINE
DCOM- 20171207
LR  - 20220311
IS  - 1499-2752 (Electronic)
IS  - 0315-162X (Linking)
VI  - 43
IP  - 5
DP  - 2016 May
TI  - Assessment of Response to Treatment, Remission, and Minimal Disease Activity in 
      Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
PG  - 918-23
LID - 10.3899/jrheum.151404 [doi]
AB  - OBJECTIVE: To assess the response to treatment, remission, and minimal disease 
      activity (MDA) in a group of patients with predominant axial psoriatic arthritis 
      (axPsA). Predictors of response were also evaluated. METHODS: Patients fulfilling 
      the ClASsification of Psoriatic ARthritis (CASPAR) criteria and treated with 
      anti-tumor necrosis factor (anti-TNF) agents adalimumab, etanercept, and 
      golimumab were enrolled and prospectively followed every 4 months for 1 year in a 
      clinical practice setting. Bath Ankylosing Spondylitis Disease Activity Index 
      (BASDAI) 50 was assessed as a set of response criteria to treatment; Composite 
      Psoriatic Disease Activity Index (CPDAI) < 4, Disease Activity Index for 
      Psoriatic Arthritis (DAPSA) score </= 3.3, and partial remission (PR) were also 
      evaluated as remission criteria. Patients were considered in MDA when they met at 
      least 5/7 of the criteria previously defined. Patients achieving BASDAI 50, PR, 
      and MDA were compared to identify outcome predictor factors. Concordance between 
      the outcome measures was also performed. RESULTS: Of the 58 patients treated with 
      anti-TNF, at baseline no patients were in PR or MDA. No patients had a CPDAI < 4 
      or a DAPSA score </= 3.3. After 12 months, BASDAI 50 was achieved in 15/48 patients 
      (31.2%). CPDAI < 4, DAPSA score </= 3.3, PR, and MDA were achieved, respectively, 
      in 17/48 (35.4%), 11/48 (22.9%), 11/48 (22.9%), and 24/48 (50%) patients. No 
      difference was found among the 3 anti-TNF. Predictors for MDA were male sex, 
      young age, low disease duration, low Health Assessment Questionnaire score, and 
      absence of enthesitis. CONCLUSION: This longitudinal observational study, based 
      on a clinical practice setting, showed that remission and MDA are achievable 
      targets in axPsA treated with anti-TNF. Predictors of remission and MDA were also 
      identified.
FAU - Lubrano, Ennio
AU  - Lubrano E
AD  - From the Academic Rheumatology Unit, Department of Medicine and Health Sciences 
      "Vincenzo Tiberio," University of Molise, Campobasso, Italy.E. Lubrano, MD, PhD, 
      Academic Rheumatology Unit, Department of Medicine and Health Sciences "Vincenzo 
      Tiberio," University of Molise; W.J. Parsons, BSc, MPH, Academic Rheumatology 
      Unit, Department of Medicine and Health Sciences "Vincenzo Tiberio," University 
      of Molise; F.M. Perrotta, MD, Academic Rheumatology Unit, Department of Medicine 
      and Health Sciences "Vincenzo Tiberio," University of Molise. 
      enniolubrano@hotmail.com.
FAU - Parsons, Wendy J
AU  - Parsons WJ
AD  - From the Academic Rheumatology Unit, Department of Medicine and Health Sciences 
      "Vincenzo Tiberio," University of Molise, Campobasso, Italy.E. Lubrano, MD, PhD, 
      Academic Rheumatology Unit, Department of Medicine and Health Sciences "Vincenzo 
      Tiberio," University of Molise; W.J. Parsons, BSc, MPH, Academic Rheumatology 
      Unit, Department of Medicine and Health Sciences "Vincenzo Tiberio," University 
      of Molise; F.M. Perrotta, MD, Academic Rheumatology Unit, Department of Medicine 
      and Health Sciences "Vincenzo Tiberio," University of Molise.
FAU - Perrotta, Fabio Massimo
AU  - Perrotta FM
AD  - From the Academic Rheumatology Unit, Department of Medicine and Health Sciences 
      "Vincenzo Tiberio," University of Molise, Campobasso, Italy.E. Lubrano, MD, PhD, 
      Academic Rheumatology Unit, Department of Medicine and Health Sciences "Vincenzo 
      Tiberio," University of Molise; W.J. Parsons, BSc, MPH, Academic Rheumatology 
      Unit, Department of Medicine and Health Sciences "Vincenzo Tiberio," University 
      of Molise; F.M. Perrotta, MD, Academic Rheumatology Unit, Department of Medicine 
      and Health Sciences "Vincenzo Tiberio," University of Molise.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20160315
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 91X1KLU43E (golimumab)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adalimumab/therapeutic use
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Psoriatic/diagnosis/*drug therapy
MH  - Etanercept/therapeutic use
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Remission Induction/methods
MH  - Severity of Illness Index
MH  - Sex Factors
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
OTO - NOTNLM
OT  - ANTI-TUMOR NECROSIS FACTOR
OT  - LONGITUDINAL STUDIES
OT  - MINIMAL DISEASE ACTIVITY
OT  - PSORIATIC ARTHRITIS
OT  - REMISSION
OT  - SPONDYLITIS
EDAT- 2016/03/17 06:00
MHDA- 2017/12/08 06:00
CRDT- 2016/03/17 06:00
PHST- 2016/01/29 00:00 [accepted]
PHST- 2016/03/17 06:00 [entrez]
PHST- 2016/03/17 06:00 [pubmed]
PHST- 2017/12/08 06:00 [medline]
AID - jrheum.151404 [pii]
AID - 10.3899/jrheum.151404 [doi]
PST - ppublish
SO  - J Rheumatol. 2016 May;43(5):918-23. doi: 10.3899/jrheum.151404. Epub 2016 Mar 15.